The biology of fetal exposure to serotonin reuptake inhibitors: Implications for neurodevelopment

Antidepressants: Pharmacology, Health Effects and Controversy

Volumn , Issue , 2012, Pages 1-26

  Galbally, Megan ^a   Lewis, Andrew J ^b   Gentile, Salvatore ^c   Walker, Susan ^d   Buist, Anne ^d  

^a MERCY HOSPITAL FOR WOMEN   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c ASL Salerno   (Italy)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874405308     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (95)

1. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM.Patterns of antidepressant medication use among pregnant women in a United States population. J. Clin. Pharmacol. 2011 Feb;51(2): 264-70.
2. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am. J. Obstet. Gynecol. 2007 Jun; 196(6):544e1-5.
3. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, et al.Use of antidepressant medications during pregnancy: a multisite study. Am. J. Obstet. Gynecol. 2008 Feb;198(2): 194 e1-5.
4. Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O.Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet. Gynecol. 2000 Apr;95(4): 487-90.
5. Bonari L, Bennett H, Einarson A, Koren G. Risks of untreated depression during pregnancy. Can. Fam. Physician 2004 Jan;50:37-9.
6. Bansil P, Kuklina EV, Meikle SF, Posner SF, Kourtis AP, Ellington SR, et al. Maternal and fetal outcomes among women with depression. J. Womens Health (Larchmt) Feb;19(2):329-34.
7. Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich LA.Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am. J. Psychiatry 2005 Jan;162(1): 79-91.
8. Austin MP, Kildea S, Sullivan E.Maternal mortality and psychiatric morbidity in the perinatal period: challenges and opportunities for prevention in the Australian setting. Med. J. Aust. 2007 Apr 2;186(7): 364-7.
9. Brettingham M.Depression and obesity are major causes of maternal death in Britain. BMJ 2004 Nov 20;329(7476): 1205.
10. Gluckman PD, Hanson MA, Cooper C, Thornburg KL.Effect of in utero and early-life conditions on adult health and disease. N. Engl. J. Med. 2008 Jul 3;359(1): 61-73.
11. O'Connor TG, Heron J, Glover V.Antenatal anxiety predicts child behavioral/emotional problems independently of postnatal depression. J. Am. Acad. Child Adolesc. Psychiatry 2002 Dec;41(12): 1470-7.
12. Hay DF, Pawlby S, Waters CS, Sharp D.Antepartum and postpartum exposure to maternal depression: different effects on different adolescent outcomes. J. Child Psychol. Psychiatry 2008 Oct;49(10): 1079-88.
13. Deave T, Heron J, Evans J, Emond A.The impact of maternal depression in pregnancy on early child development. BJOG 2008 Jul;115(8): 1043-51.
14. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, et al.Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006 Feb 1;295(5): 499-507.
15. Yonkers KA, Gotman N, Smith MV, Forray A, Belanger K, Brunetto WL, et al. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology 2011 Nov;22(6):848-54.
16. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity. JAMA: The Journal of the American Medical Association 2010; 303(1):47.
17. Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J. Affect Disord 2010 Jan;128(1-2):1-9.
18. Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Jr., Vazquez DM. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J. Perinatol. 2005 Sep;25(9): 595-604.
19. Galbally M, Lewis AJ, Lum J, Buist A. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust. N. Z. J. Psychiatry2009 Sep;43(9):846-54.
20. Mulder EJH, Ververs FFT, de Heus R, Visser GHA. Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus. Neuropsychopharmacology; 36(10):1961-71.
21. Warburton W, Hertzman C, Oberlander TF.A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr. Scand. 2010 Jun;121(6): 471-9.
22. Zeskind PS, Stephens LE.Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004 Feb;113(2): 368-75.
23. Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W.Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 2005 Feb;115(2): 411-25.
24. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W.Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J. Clin. Psychiatry 2004 Feb;65(2): 230-7.
25. Galbally M, Lewis AJ, Buist A.Developmental outcomes of children exposed to antidepressants in pregnancy. Aust. N. Z. J. Psychiatry 2011 May;45(5): 393-9.
26. Figueroa R.Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. J. Dev. Behav. Pediatr 2010 Oct;31(8): 641-8.
27. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch. Gen. Psychiatry Nov;68(11):1104-12.
28. Casper RC, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC. Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology 2011:1-9.
29. Suri R, Hellemann G, Stowe ZN, Cohen LS, Aquino A, Altushuler LL.A Prospective, Naturalistic, Blinded Study of Early Neurobehavioral Outcomes for Infants Following Prenatal Antidepressant Exposure. The Journal of clinical psychiatry 2011;72(7): 1002-7.
30. Salisbury AL, Wisner KL, Pearlstein T, Battle CL, Stroud L, Lester BM. Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment. Depression and Anxiety 2011.
31. Klinger G, Frankenthal D, Merlob P, Diamond G, Sirota L, Levinson-Castiel R, et al.Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Journal of Perinatology 2011;31(9): 615-20.
32. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2011:peds. 2008-3655v1.
33. Oberlander TF, Papsdorf M, Brain UM, Misri S, Ross C, Grunau RE. Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch. Pediatr. Adolesc. Med. May;164(5):444-51.
34. Nulman I, Koren G. The safety of fluoxetine during pregnancy and lactation. Teratology1996 May;53(5):304-8.
35. Koren G, Nulman I, Addis A. Outcome of children exposed in utero to fluoxetine: a critical review. Depress Anxiety 1998;8 Suppl 1:27-31.
36. Morison SJ, Grunau RE, Oberlander TF, Misri S, Pannikar H, Reebye P. Infant social behaviour and development in the first year of life following prolonged prenatal psychotropic medication exposure [Abstract]. Pediatric Research 2001;49(4 Pt2 Suppl):28A.
37. Mattson S, Eastvold A, Jones K, Harris J, C. C. Neurobehavioral follow-up of children prenatally exposed to fluoxetine [Abstract]. Teratology 1999;59:376.
38. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, et al.Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002 Nov;159(11): 1889-95.
39. Hekkinen T, Ekblad U, Kero P, Ekblad S, Laine K.Citalopram in pregnancy and lactation. Clinical Pharmacology Therapeutics 2002;72(2): 184-91.
40. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, et al.Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J. Pediatr. 2003 Apr;142(4): 402-8.
41. Jacobs B, Fornal C. Serotonin and behaviour, a general hypothesis. In: Bloom F, Kupfer DJ, editors. Psychopharmacology, the fourth generation in progress. New York: Raven Press; 1995. p. 461-9.
42. Mortensen JT, Olsen J, Larsen H, Bendsen J, Obel C, Sorensen HT.Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. Eur. J. Epidemiol. 2003;18(8): 769-71.
43. Misri S, Reebye P, Kendrick K, Carter D, Ryan D, Grunau RE, et al.Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am. J. Psychiatry 2006 Jun;163(6): 1026-32.
44. Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE.Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch. Pediatr. Adolesc. Med. 2007 Jan;161(1): 22-9.
45. Oberlander TF, Papsdorf M, Brain UM, Misri S, Ross C, Grunau RE.Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Archives of Pediatrics and Adolescent Medicine 2010;164(5): 444.
46. Reebye P, Morison SJ, Panikkar H, Misri S, Grunau R.Affect expression in prenatally psychotropic exposed and nonexposed mother-infant dyads. Infant Mental Health Journal 2002;23(4): 403-16.
47. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V.Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch. Gen. Psychiatry 2011 Nov;68(11): 1104-12.
48. Kolevzon A, Gross R, Reichenberg A.Prenatal and perinatal risk factors for autism: a review and integration of findings. Archives of Pediatrics and Adolescent Medicine 2007;161(4): 326.
49. Gardener H, Spiegelman D, Buka SL.Perinatal and Neonatal Risk Factors for Autism: A Comprehensive Meta-analysis. Pediatrics 2011;128(2): 344-55.
50. Saper CB. Brain Stem Modulation of Sensation, Movement, and Conciousness. In: Kandel ER, Schwartz JH, Jessell TM, editors. Principles of Neural Science. Fourth ed. United States of America: McGraw-Hill; 2000. p. 889-908.
51. Allman J. Evolving Brains. New York: Scientific American Library; 2000.
52. Whitaker-Azmitia PM. Serotonin and Development. Handbook of Behavioral Neuroscience; 21:309-23.
53. Pawluski JL. Perinatal Selective Serotonin Reuptake Inhibitor Exposure: Impact on Brain Development and Neural Plasticity. Neuroendocrinology2011.
54. Allman JM. Evolving Brains. New York: Scientific American Library; 1999.
55. Kandel ER, Schwartz JH, Jessell TM. Principles of neural science: McGraw-Hill New York; 2000.
56. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. Seventh ed. New York: Oxford University Press; 1996.
57. Rice D, Barone Jr S. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models Environ Health Perspect 108 (suppl 3): 511â€"533. Find this article online2000.
58. Stanwood GD, Levitt P. The Effects of Monoamines on the Developing Nervous System. In: Nelson CA, Luciana M, editors. Handbook of Developmental Cognitive Neuroscience. Cambridge: MIT Press; 2008.
59. Whitaker-Azmitia PM, Druse M, Walker P, Lauder JM. Serotonin as a developmental signal. Behavioural brain research 1996;73(1-2):19.
60. Lauder JM.Ontogeny of the Serotonergic System in the Rat: Serotonin as a Developmental Signala. Annals of the New York Academy of Sciences 1990;600(1): 297-313.
61. Borue X, Chen J, Condron BG. Developmental effects of SSRIs: lessons learned from animal studies. International Journal of Developmental Neuroscience2007;25(6):341-7.
62. Andrews MH, Matthews SG. Programming of the hypothalamo-pituitary-adrenal axis: serotonergic involvement. Stress: The International Journal on the Biology of Stress2004;7(1):15-27.
63. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am. J. Psychiatry2003 May;160(5):993-6.
64. Rampono J, Proud S, Hackett LP, Kristensen JH, Ilett KF.A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. Int. J. Neuropsychopharmacol. 2004 Sep;7(3): 329-34.
65. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C.Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br. J. Psychiatry. 2008 May;192(5): 338-43.
66. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G.Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Archives of Pediatrics and Adolescent Medicine 2006;160(2): 173.
67. Mulder EJH, Ververs FFT, de Heus R, Visser GHA.Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus. Neuropsychopharmacology 2011;36(10): 1961-71.
68. Mayes LC, Ward A. Principles of Neurobehavioural Teratology. In: Cicchetti D, Walker EF, editors. Neurodevelopmental Mechanisms in Psychopathology. Cambridge: Cambridge University Press; 2003. p. 3-34.
69. Edwards JG. Unwanted effects of psychotropic drugs 2: Drug interactions, effects during pregnancy and breast feeding, pharmaco-vigilance and medico-legal considerations. In: King DJ, editor. Seminars in Clincal Psychopharmacology. Second ed. London: Royal College of Psychiatrists; 2005. p. 601-61.
70. Rayen I, van den Hove DL, Prickaerts J, Steinbusch HW, Pawluski JL.Fluoxetine during Development Reverses the Effects of Prenatal Stress on Depressive-Like Behavior and Hippocampal Neurogenesis in Adolescence. PLoS One 2011;6(9): e24003.
71. Hodes GE, Hill-Smith TE, Suckow RF, Cooper TB, Lucki I.Sex-specific effects of chronic fluoxetine treatment on neuroplasticity and pharmacokinetics in mice. Journal of Pharmacology and Experimental Therapeutics 2010;332(1): 266-73.
72. Lee LJ.Neonatal fluoxetine exposure affects the neuronal structure in the somatosensory cortex and somatosensory-related behaviors in adolescent rats. Neurotoxicity research 2009;15(3): 212-23.
73. Swerts CAS, Costa AMDD, Esteves A, Borato CES, Swerts MSO.Effects of fluoxetine and imipramine in rat fetuses treated during a critical gestational period: a macro and microscopic study. Revista Brasileira de Psiquiatria 2010;32(2): 152-8.
74. Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, Buelke-Sam J.A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Toxicological Sciences 1994;23(2): 194-205.
75. Lee HJ, Kim JW, Yim SV, Kim MJ, Kim SA, Kim YJ, et al.Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats. Mol. Psychiatry 2001 Nov;6(6): 610, 725-8.
76. Pawluski JL, Galea LAM, Brain U, Papsdorf M, Oberlander TF.Neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors. Pediatrics 2009;124(4): e662-e70.
77. Devlin AM, Brain U, Austin J, Oberlander TF.Prenatal exposure to maternal depressed mood and the MTHFR C677T variant affect SLC6A4 methylation in infants at birth. PLoS One 2010;5(8): e12201.
78. Bairy K, Madhyastha S, Ashok K, Bairy I, Malini S. Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology-Basel-2007;79(1):1.
79. Zusso M, Debetto P, Guidolin D, Barbierato M, Manev H, Giusti P.Fluoxetine-induced proliferation and differentiation of neural progenitor cells isolated from rat postnatal cerebellum. Biochemical pharmacology 2008;76(3): 391-403.
80. Laine K, Heikkinen T, Ekblad U, Kero P.Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch. Gen. Psychiatry 2003 Jul;60(7): 720-6.
81. Oberlander TF, Bonaguro RJ, Misri S, Papsdorf M, Ross CJ, Simpson EM.Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol. Psychiatry 2008 Jan;13(1): 65-73.
82. Anderson GM, Czarkowski K, Ravski N, Epperson CN.Platelet serotonin in newborns and infants: ontogeny, heritability, and effect of in utero exposure to selective serotonin reuptake inhibitors. Pediatric research 2004;56(3): 418.
83. Epperson CN, Jatlow PI, Czarkowski K, Anderson GM.Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breastfeeding mother-infant pairs. Pediatrics 2003;112(5): e425.
84. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA. Early-life blockade of the 5-HT transporter alters emotional behaviour in adult mice. Science 2004;306:879-81.
85. Lisboa S, Oliveira P, Costa L, Venã¢ncio E, Moreira E.Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology 2007;80(1): 49.
86. Kusakawa S, Nakamura K, Miyamoto Y, Sanbe A, Torii T, Yamauchi J, et al.Fluoxetine promotes gliogenesis during neural differentiation in mouse embryonic stem cells. Journal of neuroscience research 2010;88(16): 3479-87.
87. Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RCS, et al.Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2005;31(1): 47-57.
88. Weaver KJ, Paul IA, Lin R, Simpson KL. Neonatal Exposure to Citalopram Selectively Alters the Expression of the Serotonin Transporter in the Hippocampus: Dose―Dependent Effects. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology2010.
89. Olivier JDA, Vallãs̈ A, van Heesch F, Afrasiab-Middelman A, Roelofs JJPM, Jonkers M, et al. Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring. Psychopharmacology 2011:1-14.
90. Vartazarmian R, Malik S, Baker GB, Boksa P. Long-term effects of fluoxetine or vehicle administration during pregnancy on behavioral outcomes in guinea pig offspring. Psychopharmacology (Berl)2005 Mar;178(2-3):328-38.
91. Gluckman PD, Hanson MA. The Developmental Origins of Health and Disease. Early Life Origins of Health and Disease2006:1-7.
92. Goldberg AD, Allis CD, Bernstein E.Epigenetics: A landscape takes shape. Cell 2007;128(4): 635-8.
93. Van den Bergh BRH, Mulder EJH, Mennes M, Glover V.Antenatal maternal anxiety and stress and the neurobehavioural development of the fetus and child: links and possible mechanisms. A review. Neuroscience and Biobehavioral Reviews 2005;29(2): 237-58.
94. 2-HSD2. Psychoneuroendocrinology 2011.
95. Glover V, O'Connor T, O'Donnell K.Prenatal stress and the programming of the HPA axis. Neuroscience and Biobehavioral Reviews 2010;35(1): 17-22.